| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-499
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-499 |
| filingDate |
2017-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102465757-B1 |
| titleOfInvention |
Spiro-lactam NMDA receptor modulators and uses thereof |
| abstract |
Compounds with potency in modulating NMDA receptor activity are disclosed. Such compounds may be used in the treatment of conditions such as depression and related disorders. Also disclosed are oral delivery formulations of the present compound, and other pharmaceutically acceptable delivery forms, including intravenous formulations. |
| priorityDate |
2016-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |